Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy consists of **AlloDerm** (a regenerative tissue matrix) and **Emdogain** (an enamel matrix derivative) used for the treatment of gingival recession. AlloDerm, manufactured by BioHorizons, is an acellular dermal matrix (ADM) derived from human cadaveric tissue that has been processed to remove cells while preserving a bioactive collagen scaffold. It serves as a structural framework for host cell migration and tissue ingrowth. Emdogain, manufactured by Straumann, is a biologic product containing porcine-derived enamel matrix proteins, primarily amelogenins. These proteins trigger the biological processes of natural tooth development, promoting the regeneration of periodontal attachment, including cementum, periodontal ligament, and alveolar bone. In clinical trials conducted at the **University of Louisville**, this combination is typically applied using a coronally positioned tunnel technique to achieve root coverage and increase keratinized tissue width in patients with Miller class 1 or 2 gingival recession.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AlloDerm + Emdogain.